C4 Therapeutics' Series A Round

C4 Therapeutics raised a round of funding on January 07, 2016.

C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. The company's Degronimid platform incorporates highly selec…

Articles about C4 Therapeutics' Series A Round: